Article
Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Cancer gene therapy - 1 Feb 2000
Coukos G, Makrigiannakis A, Montas S, Kaiser L R, Toyozumi T, Benjamin I, Albelda S M, Rubin S C, Molnar-Kimber K L
Abstract excerpt
Recombinant strains of herpes simplex virus-1 (HSV-1) harboring mutations in the infected cell product (ICP)34.5 region lose their neurovirulence and replicate more efficiently in dividing tumor cells than stationary cells, becoming replication-selective oncolytic agents. Additional mutation of the ICP6 gene, which encodes ribonucleotide reductase, further impairs the ability of HSV-1 mutants to replicate in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.